Psoriasis biologics landscape, 2026 mid-year reference

Reference layout of the psoriasis biologic class as of mid-2026. Includes approved mechanisms, first-line versus later-line positioning, the IL-23 dominance picture, and the live commercial questions for the class. Useful as a quick orientation for cross-functional teams entering the psoriasis conversation, with deeper analysis available in companion gated Briefs on real-world switching, treat-to-target adoption, and the second-generation pipeline.